Immunotherapy is a type of cancer treatment that uses the body's own immune system to help fight cancer. This is by stimulating the immune response to recognize and attack cancer cells more effectively.
National University of Singapore, Yong Loo Lin School of Medicine Sep 16 2024 Immunotherapy is a type of cancer treatment that uses the body's own immune system to help fight cancer. This is by stimulating the immune response to recognize and attack cancer cells more effectively. The treatment involves using substances that boost the immune system, teaching immune cells to target cancer, or using engineered cells to specifically target and kill cancer cells.
In the study, the researchers developed a technique which modified EVs to carry multiple immune-boosting molecules called 'immunomodulatory ligands', for the treatment of in vivo models of metastatic pancreatic cancer and melanoma. The approach enhanced the therapeutic effectiveness of the ligands-;particularly the subset tumor Necrosis Factor Receptor Superfamily agonists, which are key in controlling immune responses against cancer.
Asst Prof. Minh Le said, "We are thrilled to present this novel EV-based delivery system that not only enhances the therapeutic efficacy of immunomodulatory ligands but also significantly reduces systemic toxicity. Our findings pave the way for safer and more effective cancer immunotherapies, potentially transforming the landscape of cancer treatment."
Cancer Immunotherapy Immunotherapy Medicine Cancer Treatment Efficacy Immune Response Immune System Immunomodulatory Inflammation Pharmacology
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New multimodal signature could predict immunotherapy successAn international team of researchers led by Francesca Finotello from the Digital Science Center (DiSC) and the Department of Molecular Biology has derived a molecular signature from tumor transcriptomics data that quantifies the main sources of heterogeneity in the tumor microenvironment.
Read more »
Immunotherapy before and after lung cancer surgery reduces death risk and disease recurrence, research findsPeople with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to a new analysis by Johns Hopkins Kimmel Cancer Center investigators.
Read more »
Immunotherapy before and after surgery benefits NSCLC patientsPeople with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to a new analysis by Johns Hopkins Kimmel Cancer Center investigators.
Read more »
Double trouble for triple-negative breast cancer: Two-pronged strategy restores immunotherapy sensitivityA team of MUSC Hollings Cancer Center researchers has discovered one way in which triple-negative breast cancer (TNBC) cells become resistant to immunotherapy and have tested a two-pronged treatment strategy that was able to restore sensitivity to immunotherapy in a preclinical model.
Read more »
Study identifies five key factors that predict response of cancer patients to immunotherapyA team of researchers at IRB Barcelona has identified five independent factors that predict cancer patients' response to checkpoint inhibitors (CPIs). The study, which has been published in Nature Genetics, validates these factors in more than 1,400 patients and diverse types of cancer.
Read more »
Five key factors identified for predicting immunotherapy response in cancer patientsImmunotherapy has transformed cancer treatment in recent years by enabling the immune system to attack tumor cells.
Read more »